Thromboxane B2 and Platelet Function Testing as Measures of Aspirin Resistance in Hong Kong Chinese Patients

Plain-language summary

This study examines thromboxane B2 and platelet function tests, using blood samples, to assess aspirin resistance in Hong Kong Chinese patients taking aspirin. It enrolled patients aged 18 and older who were taking long-term low-dose aspirin for stable coronary heart disease. It was a non-phased study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Chinese University of Hong Kong

Intervention

Blood samples will be taken to assess platelet function. There is no change in treatment.

Start date

4/2/2015

Estimated completion

4/1/2021

Countries

Hong Kong

Related genes

Locations

• Hong Kong, Hong Kong

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients aged ≥ 18 years who have a history of stable CHD receiving long-term mono-antiplatelet therapy with aspirin (80 mg once daily) for reducing cardiovascular risk will be recruited from the outpatient clinic.

Exclusion Criteria:

* Patients who are currently taking ticlopidine, clopidogrel, dipyridamole or other antiplatelet / antithrombotic agents will not be recruited.
* Patients who are on regular therapy with anti-inflammatory drugs, or others drugs containing aspirin or non-steroid anti-inflammatory drugs (NSAIDS), or traditional Chinese medicine that have direct effects on the haemostatic system, such as angelica, danshen, garlic, ginger, ginkgo and motherwort will not be included unless they are willing to stop these treatments for at least 2 weeks
* Patients will not be recruited if they had MI, stroke, coronary artery bypass surgery or other revascularization procedure, unstable angina or angioplasty within 3 months of screening.